Prognostic value of genomic mutations in metastatic prostate cancer()()

Metastatic prostate cancer (mPC) has a poor prognosis, and new treatment strategies are currently being offered for patients in clinical practice, but mPC is still incurable. A considerable proportion of patients with mPC harbor homologous recombination repair (HRR) mutations, which may be more sens...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Honghui, Ding, Yi, Huang, Hang, Lin, Qi, Chen, Wei, Yu, Zhixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988500/
https://www.ncbi.nlm.nih.gov/pubmed/36895385
http://dx.doi.org/10.1016/j.heliyon.2023.e13827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988500/
https://www.ncbi.nlm.nih.gov/pubmed/36895385
http://dx.doi.org/10.1016/j.heliyon.2023.e13827

Ejemplares similares